Peter Lynch · Growth at a reasonable price (GARP)
Is Apellis Pharmaceuticals, Inc. (APLS) a Peter Lynch Stock?
Strong GARP candidate: growth at a reasonable price.
77/100
Mitigé
3/6 critères validés
Les critères de Peter Lynch, appliqués à APLS
PEG ≤ 1.0
clé-
EPS CAGR ≥ 15%
clé-
Revenue CAGR ≥ 10%
97.1%
Net margin > 0
12.1%
Comment APLS se classe selon d'autres stratégies
Données financières en direct
Cap. boursière
$5.25B
PER (TTM)
38.8x
ROIC (TTM)
18.11%
Marge brute
90.12%
Autres analyses Peter Lynch
Questions fréquentes
What is APLS's Peter Lynch fit score?
APLS scores 77/100 on our Peter Lynch fit engine. Strong GARP candidate: growth at a reasonable price.
Does Peter Lynch actually own APLS?
Our score is computed from financial fundamentals against Peter Lynch's published criteria. We don't claim that Peter Lynch personally owns or recommends APLS.
How often is this score updated?
APLS's Peter Lynch fit score is recomputed daily from the latest TTM financials. The page below shows when it was last refreshed.
Outil éducatif, pas un conseil en investissement. Les scores sont calculés à partir de données financières publiques selon les critères publiés de chaque stratégie d'investissement. Nous ne prétendons pas que Peter Lynch possède ou recommande APLS personnellement.
